Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion type Assertion NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_head.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion description "[EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_provenance.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion evidence source_evidence_literature NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_provenance.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion SIO_000772 16236351 NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_provenance.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion wasDerivedFrom befree-20140225 NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_provenance.
- NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_assertion wasGeneratedBy ECO_0000203 NP860708.RAQcjd-jTJwKcFUBgEyX0sEXu2ZsuiIFdC57cCAl-9xZE130_provenance.